Results 71 to 80 of about 755,616 (163)

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

Development of a Scalable Synthesis of a Bruton’s Tyrosine Kinase Inhibitor via C–N and C–C Bond Couplings as an End Game Strategy

open access: yes, 2016
A scalable and convergent synthesis of a BTK (Bruton’s tyrosine kinase) inhibitor has been developed. Synthetic routes to key intermediates were explored for the scale-up campaign, especially the process for 6-dimethylaminodihydroisoquinolinone, which ...
Keshab Sarma (1692565)   +8 more
core   +2 more sources

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

New anti‐inflammatory and remodelling drugs for unmet clinical needs in severe asthma and chronic obstructive pulmonary disease (COPD)

open access: yesBritish Journal of Pharmacology, EarlyView.
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β2‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids ...
Ian M. Adcock
wiley   +1 more source

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

open access: yes, 2018
Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies.
Robert Campbell   +2 more
core   +1 more source

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy

open access: yesCancer Science, EarlyView.
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao   +8 more
wiley   +1 more source

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib

open access: yesCase Reports in Infectious Diseases, 2016
Cryptococcus is a unique environmental fungus that can cause disease most often in immunocompromised individuals with defective cell-mediated immunity. Chronic lymphocytic leukemia (CLL) is not known to be a risk factor for cryptococcal disease although ...
Koh Okamoto   +2 more
doaj   +1 more source

Phylogeny of Tec Family Kinases: Identification of a Pre-Metazoan Origin of Btk, Bmx, Itk, Tec, Txk and the Btk Regulator SH3BP5 [PDF]

open access: yes, 2008
It is generally considered mammals and birds have five Tec family kinases (TFKs): Btk, Bmx (also known as Etk), Itk, Tec, and Txk (also known as Rlk). Here, we discuss the domains and their functions and regulation in TFKs.
Ortutay, Csaba   +11 more
core   +2 more sources

T‐Cell Response After SARS‐CoV‐2 Vaccination in Patients With Hematological Malignancy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Patients with hematologic malignancies (HM) often mount poor humoral responses to SARS‐CoV‐2 vaccination due to their immunocompromised status. Protection against severe COVID‐19 is strongly related to cellular immunity, yet vaccine‐induced T‐cell responses remain incompletely characterized.
L. S. Boerenkamp   +7 more
wiley   +1 more source

AustrAIHANZ – consensus guidelines on the investigation and management of autoimmune haemolytic anaemia in Australia and New Zealand

open access: yesInternal Medicine Journal, EarlyView.
Abstract Autoimmune haemolytic anaemia is a rare immune‐mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end‐organ ...
Philip Choi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy